AstraZeneca to Buy China's Gracell Bio for up to $1.2 Billion https://ift.tt/DujJaOk cash deal, which adds several experimental therapies to AstraZeneca's portfolio, values Gracell at $2 per ordinary share, or $10 per ADS of Gracell, plus a non-tradable contingent value right of $0.30 per ordinary share, if certain regulatory milestones are met.
Tuesday, December 26, 2023
AstraZeneca to Buy China's Gracell Bio for up to $1.2 Billion
Subscribe to:
Post Comments (Atom)
-
Jeffersonville, OH - Join our 100% Owner Operator Fleet today! If you're tired of uncertain work, if fuel prices are killing your profit...
-
Genesis HealthCare - Florence, KY - Offering $2000 Sign On Bonuses for Full Time LPNs! Now Under New Leadership! Now offering OnShift! Acces...
-
Amid demands to defer the Bihar assembly elections due to Covid-19, Chief Election Commissioner Sunil Arora says all necessary preparations ...
No comments:
Post a Comment